Recardio

Regenerative Cardiac Medicine of Tomorrow

  • Company
    • Profile
    • Management Board
    • Boards
    • Awards
  • Pipeline
    • Background
    • Rationale
    • Therapy
  • Clinical Studies
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News & Events
    • Meet us at
  • Careers
Learn how we approach
Regenerative Cardiac
Medicine of Tomorrow

RECARDIO’S Profile

RECARDIO (REgenerative CARDIOvascular Therapy) is a clinical-stage life science company focusing on drug based regenerative therapies for cardiovascular diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe.

Read more

Regenerative cardiac therapy

RECARDIO’s lead drug dutogliptin, a DPP-IV inhibitor, demonstrated significant effects in activating cardiac regeneration. The clinical program presents a therapeutic platform for cardiovascular patients, with potential of improving heart function, quality of life and survival.

Read more

News / Events

Recardio’s Phase 2 Regenerative Post-Myocardial Infarction Trial of Dutogliptin Enrolled First Patients and Recruiting in Multiple Centers

December 13, 2018

Recardio at BIO Investor Forum 2018 in San Francisco

October 17, 2018

Recardio presents at the 2018 Annual Meeting of the European Society of Cardiology in Munich

August 25, 2018

Read More

Clinical Studies

RECARDIO’s global and multicenter Phase 2B study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with acute myocardial infarction.

 

 

 

Read More

Careers

Being located in the US and Europe, we are committed to develop the regenerative therapies of the future. To support our clinical development, we are continuously looking for expanding our team.

 

 

 

Read More

  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2019 · All Rights Reserved

Copyright © 2019 · Altitude Pro Theme on Genesis Framework · WordPress · Log in